In the latter case, a number of pathway targeting drugs – such as statins that inhibit the mevalonate pathway (33), imatinib inhibiting PDGFRβ (22), or COMAPSS complex inhibitors (27) – can cause increased cell death in mutant p53 vs. wild-type p53-bearing cancer cells. Here, TP53 is linked to cancer.